A Quarterly Newsletter Produced by Labtician Ophthalmics
Issue 1 - January 2026
Polydor Strouthos, President
Labtician Ophthalmics, Oakville, ON
Newsletter to Help Your Practice and Patients Thrive
Welcome to Sightline! This quarterly newsletter brings you valuable insights, updates, and opportunities designed to help your practice — and your patients — thrive. Beyond product and innovation updates, Sightline celebrates the power of community in advancing eye health. Each issue highlights ophthalmic community initiatives, collaborative programs, and success stories from practices and professionals who are making an impact every day.
As a trusted partner, please contact us with any questions, feedback or suggestions about content you would like to see in Sightline. Together, we can continue to strengthen our shared goal — improving the visual health and quality of life of patients everywhere.
NEW Easy-to-Use Single Unit Doses of Game Changing Lab™TRIACTIV Now Available in Canada
Renowned for its groundbreaking formulation, LabTRIACTIV is the only preservative-free artificial tear in Canada that targets all three layers of the tear film, resulting in fewer applications. Already being called a “game changer” by Eye Care Professionals, with the introduction of 30 Single Unit Dose dispensers, accessing this revolutionary product has never been easier.
Dr. Mark Eltis, President of the College of Optometrists of Ontario and Canadian Ambassador for the American Board of Optometry, and one of the Eye Care Professionals in the clinical trials, calls it “the best single-unit mechanism that I’ve ever seen,” and for good reason.
Imagine your Dry Eye patients being able to enjoy long-lasting relief with the premium option of easy-to-use single-unit dispensers. LabTRIACTIV’s single doses make it simple to forget about their dry eyes and focus on living their life.
Don’t let Dry Eyes hold your patients back any longer. Recommend LabTRIACTIV today and watch your patients experience the transformative relief that countless others are raving about. They deserve to enjoy comfort without the hassle.
Help your patients take the first step towards a brighter, clearer tomorrow!
NEW Eye Beauty Collective to Become Go-To for Info on Beauty Trends and Eye Health
In this issue, our Spotlight is on Dr. Janice Luk, who has lectured at leading conferences, including the Canadian Dry Eye Summit and the Lash Conference. Dr. Luk shares with us the latest trends and challenges in eye care and her vision for a new Eye Beauty Collective to become the go-to for accessible information on beauty trends and eye health.
How Lab™RELEEV is the New Standard in Corneal Edema Management
For over 40 years, patients with corneal edema have had only one hypertonic treatment option—an uncomfortable solution associated with burning, stinging, and poor tolerance that challenged compliance. It was a harsh necessity, not an ideal choice. LabRELEEV changes that.
As the first and only hypertonic line in Canada to include sodium hyaluronate, LabRELEEV is designed to soothe the eye while reducing corneal swelling. Sodium hyaluronate hydrates and protects the ocular surface, helping to relieve irritation and improve tolerability compared to traditional hypertonics.
LabRELEEV provides 24-hour management with its dual formulas:
- LabRELEEV Day – preservative-free drops with 13.5% sorbitol as the hypertonic agent, paired with sodium hyaluronate for hydration and comfort
- LabRELEEV Night – a 4.5% sodium chloride ointment enriched with sodium hyaluronate, providing prolonged overnight action and easing morning eyelid opening
LabRELEEV is suitable for both acute (post-surgical) and chronic cases, such as Fuchs’ endothelial dystrophy or bullous keratopathy. Clinical evidence shows that patients treated with LabRELEEV formulations after cataract surgery achieved faster resolution of corneal edema, improved comfort, and earlier recovery of visual acuity compared to standard regimens.
For eye care professionals, LabRELEEV represents the next generation of hypertonic therapy—bringing both efficacy and comfort to patients who previously had to settle for less.
Lab™AMNIO: Confidence Backed by AATB Accreditation
Labtician Ophthalmics is proud to reintroduce LabAMNIO, our dehydrated amniotic membrane allograft designed to support ocular surface healing in a wide spectrum of corneal and conjunctival conditions. LabAMNIO now carries a unique distinction; it is sourced from an American Association of Tissue Banks (AATB) accredited facility.
AATB accreditation is globally recognized as the benchmark for tissue banking quality and ethics. It is one of the most challenging and respected achievements in tissue banking.
Achieving accreditation requires compliance with stringent standards for donor consent, serologic screening, tissue processing, traceability, and facility inspection. Currently, only 129 accredited institutions worldwide hold AATB accreditation. This status provides a rare assurance of both safety and consistency.
Ongoing rigorous audits to maintain accreditation ensure that safety, quality, and traceability are not just met once but consistently upheld over time.
For clinicians, this means greater confidence in safety, traceability, and consistency—all critical considerations when selecting tissue for patient care. In fact, AATB accreditation is a requirement for Canadian hospitals and eye banks when choosing commercial amniotic membrane products.
LabAMNIO continues to offer:
- Strong regenerative properties
- Easy in-office use
- Selection of shapes, sizes and thicknesses, all at the same price
- Room temperature storage
By combining the regenerative healing benefits of amniotic membrane with the assurance of AATB-accredited sourcing, LabAMNIO gives eye care professionals and their patients’ confidence at every step of care.
Labtician Supports Canadian Association of Optometrists’ Policy on Myopia Management
Labtician is proud to support the Canadian Association of Optometrists’ (CAO) policy position that endorses evidence-based myopia management as a standard of care for all at-risk patients¹. Labtician is enabling access to pharmaceutical myopia control with the launch of the new low-dose Labtician Atropine.
Labtician Atropine provides eye care professionals with ready-to-use, precision-manufactured atropine drops to ensure consistent dosing. Available in four precise concentrations 0.01%, 0.02%, 0.025% and 0.05%, Labtician Atropine allows customization of treatment to patient needs and physician preference.
We provide direct-to-patient shipping anywhere in Canada through our pharmacy partners or your preferred retail pharmacy. For more information, email isrs@labtician.com
See What Eye Care Professionals Have to Say
“I’m definitely excited (that LabTRIACTIV is available now in Single Unit Doses) for both patients and personal reasons. I know if I’m travelling somewhere or have a long day of meetings or something I don’t want to be shoving a bottle in my pocket so having those little minums on hand is quite convenient. Patients are getting that long, long, lasting relief. I even have two, maybe three, patients who are on anti-inflammatory drops long-term. We’ve actually discontinued the medication and use this instead.”
Dr. Jonathan Akle
Emerald Hills Eye Care In Sherwood Park, AB
As a trusted parter let us know who you would like to see featured in The Spotlight, and what topics you would like to see covered in a future issue of Sightline. (Digitalmarketing@labtician.com)